tiprankstipranks
Generic Sweden AB (SE:GENI)
:GENI
Sweden Market

Generic Sweden AB (GENI) AI Stock Analysis

1 Followers

Top Page

SE:GENI

Generic Sweden AB

(GENI)

Select Model
Select Model
Select Model
Outperform 75 (OpenAI - 5.2)
Rating:75Outperform
Price Target:
kr39.00
▼(-16.04% Downside)
Action:ReiteratedDate:02/18/26
The score is driven primarily by strong financial performance (profitable growth, strong cash generation, and a debt-free balance sheet). Valuation is supportive with a moderate P/E and solid dividend yield. Offsetting these positives, technicals are weak with the price below major moving averages and bearish momentum signals.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces financial risk and interest burden, giving management flexibility to fund growth, invest in R&D, return capital, or weather downturns without refinancing pressure. This durability supports sustainable operations and strategic optionality.
Negative Factors
Gross margin compression
Declining gross margin over several years signals higher delivery costs, pricing pressure, or product mix shifts that could erode long-term profitability. If structural, margin compression limits ability to sustain operating margins and investment without offsetting revenue growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces financial risk and interest burden, giving management flexibility to fund growth, invest in R&D, return capital, or weather downturns without refinancing pressure. This durability supports sustainable operations and strategic optionality.
Read all positive factors

Generic Sweden AB (GENI) vs. iShares MSCI Sweden ETF (EWD)

Generic Sweden AB Business Overview & Revenue Model

Company Description
Generic Sweden AB, a technology company, provides messaging services for all applications. It also offers a platform for digital communication services. The company was incorporated in 1993 and is headquareted in Stockholm, Sweden....

Generic Sweden AB Financial Statement Overview

Summary
Strong multi-year revenue growth with a sharp re-acceleration in 2025, sustained double-digit profitability, robust free cash flow that closely tracks earnings, and a debt-free balance sheet. Key risks are declining gross margin over time and some historical variability in cash conversion.
Income Statement
86
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
88
Very Positive
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue183.71M176.45M142.59M127.73M114.23M
Gross Profit38.58M44.72M38.27M35.54M31.93M
EBITDA39.58M35.52M30.16M26.75M24.16M
Net Income31.04M27.25M23.31M20.45M18.13M
Balance Sheet
Total Assets105.14M88.97M77.42M68.04M59.42M
Cash, Cash Equivalents and Short-Term Investments58.24M40.62M37.20M32.60M31.07M
Total Debt0.000.000.000.000.00
Total Liabilities38.55M33.75M31.01M29.57M29.11M
Stockholders Equity66.59M55.22M46.41M38.47M30.31M
Cash Flow
Free Cash Flow38.98M21.85M19.97M13.82M18.44M
Operating Cash Flow39.73M24.06M21.84M16.85M19.89M
Investing Cash Flow-2.44M9.79M-13.87M-3.03M-1.45M
Financing Cash Flow-19.67M-18.44M-15.37M-12.29M-9.83M

Generic Sweden AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
kr429.61M18.383.48%
68
Neutral
kr351.92M24.404.69%
62
Neutral
kr198.88M-160.323.25%-18.05%-71.19%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:GENI
Generic Sweden AB
34.95
-21.44
-38.02%
TFSVF
24SevenOffice
0.99
0.89
908.16%
DE:1CW
Sleep Cycle AB
1.49
-2.22
-59.95%
DE:BOJB
BIMobject AB
0.42
-0.29
-41.08%
SE:UPSALE
Upsales Technology AB
20.90
-13.79
-39.75%
SE:CDMIL
Codemill AB
14.60
-7.56
-34.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 18, 2026